Two cases of meningitis associated with ocrelizumab therapy.

Ocrelizumab is a monoclonal anti-CD20 antibody approved for the treatment of both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Its increasing use for MS has been due in part to its efficacy, unique indication for PPMS, and convenient dosing, combined with a favorable side effect and risk profile. In this case report we describe two cases of meningitis developing within 1 year of initiating ocrelizumab therapy in patients with multiple sclerosis (MS).